Illumina is working on a series of oncology partnerships that aim to expand the reach of its comprehensive genomic profiling family of products, TruSight Oncology.
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.
